Table 1:

Summary of individual studies and outcome measures.

Study	Sample Size, Study Duration	Treatment, Primary Eye	Treatment, Contralateral Eye	Analysis
Confocal Microscopy/MB Distribution	n=13 total BN rats, euthanized at: 10 mins post injection (n=5), 20 mins post injection (n=3), 30 mins post injection (n=5)	30 mM MB (5O ul, retrobulbar)	HBSS (50 ul, retrobulbar)	Confocal microscopy: MB transport to sclera
Scleral Stiffening in Rats Euthanized at Day 0 (Immediately After Treatment)	n=7 BN rats, euthanized immediately post treatment	3 mM MB (100 ul retrobulbar), illumination*	HBSS (100 ul, retrobulbar)	Whole globe inflation: scleral strain
Scleral Stiffening in Rats Euthanized 6 Weeks After Treatment	n=8 BN rats, euthanized 6 weeks post treatment	3 mM MB (100 ul retrobulbar), illumination*	HBSS (100 ul, retrobulbar)	Whole globe inflation: scleral strain Electroretinography: retinal function Axon Count/Grade: ON/retinal health
Histology (MB+light)	n=3 BN rats, euthanized 10 days post treatment	3 mM MB (100 ul retrobulbar), illumination*	N/A**	Histology: ON/retinal morphology
Histology (Light Only)	n=3 BN rats, euthanized 10 days post treatment	Illumination*	N/A**	Histology: ON/retinal morphology OCT: retinal morphology

Abbreviations: MB (methylene blue), BN (Brown Norway), HBSS (Hank's Balanced Salt Solution), ON (Optic Nerve), OCT (Optical Coherence Tomography),

^*Illumination was performed using a 30 minute transpupillary exposure of the peripapillary sclera to 424 m W/cm2 660 nm light.

^**Naive (untreated) controls.